onvansertib (PCM-075) / Cardiff Oncology 
Welcome,         Profile    Billing    Logout  
 1 Disease   6 Trials   6 Trials   338 News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
onvansertib (PCM-075) / Cardiff Oncology
NCT03414034: Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Checkmark In combination with Zytiga in mCRPC at EMUC 2019
Nov 2019 - Nov 2019: In combination with Zytiga in mCRPC at EMUC 2019
Checkmark In combination with Zytiga in patients with mCRPC
Feb 2019 - Feb 2019: In combination with Zytiga in patients with mCRPC
Completed
2
72
US
Onvansertib, PCM-075, Abiraterone, Prednisone
Cardiff Oncology
Metastatic Castration-Resistant Prostate Cancer
10/23
10/23
NCT04752696: Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma

Completed
2
43
US
Onvansertib, PCM-075, Nanoliposomal irinotecan, Onivyde, Nal-IRI, Leucovorin, Fluorouracil, 5-FU
Cardiff Oncology
Pancreatic Ductal Adenocarcinoma
12/24
12/24
NCT06398587: Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Withdrawn
2
35
US
Onvansertib, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, PLK1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Electrocardiography, ECG, EKG, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Biospecimen Collected, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
OHSU Knight Cancer Institute, Oregon Health and Science University
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
05/26
06/27
ONSEMBLE, NCT05593328: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Completed
2
23
US
Onvansertib, FOLFIRI, Bevacizumab
Cardiff Oncology
Colorectal Cancer, Metastatic Colorectal Cancer
12/24
12/24
CRDF-004, NCT06106308: Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation

Recruiting
2
90
US
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Cardiff Oncology, Pfizer
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
11/26
01/27
NCT05450965: Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Recruiting
2
37
US
Onvansertib
Taofeek Owonikoko, Cardiff Oncology, National Cancer Institute (NCI)
Small-cell Lung Cancer, Small Cell Lung Carcinoma
08/27
11/27
NCT03829410: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Checkmark Data from trial in combination with Folfiri and bevacizumab for metastatic CRC at ESMO 2022
Sep 2022 - Sep 2022: Data from trial in combination with Folfiri and bevacizumab for metastatic CRC at ESMO 2022
Checkmark Data rom trial in combination with Folfiri and bevacizumab for metastatic colorectal cancer
Jan 2022 - Jan 2022: Data rom trial in combination with Folfiri and bevacizumab for metastatic colorectal cancer
Completed
1/2
68
US
Onvansertib, PCM-075, Bevacizumab, Avastin®, FOLFIRI
Cardiff Oncology
Metastatic Colorectal Cancer, KRAS Gene Mutation
01/24
01/24
PANCONVA, NCT06736717: Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Recruiting
1/2
21
US
Onvansertib, PCM-075, NMS-1286937, NALIRIFOX
University of Kansas Medical Center, Cardiff Oncology
Pancreatic Cancer
07/26
01/27
NCT05383196: Onvansertib + Paclitaxel in TNBC

Active, not recruiting
1/2
50
US
Onvansertib, NMS-1286937, Paclitaxel, Paclitaxel Injection
Antonio Giordano, MD, Cardiff Oncology
Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
02/26
02/29
NCT04005690: Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
1
90
US
Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Onvansertib, 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Azenosertib, ZN-c3, KP-2638, C29H34N8O2, Saruparib, AZD5305, 2589531-76-8, AZD 5305, AZD-5305, PARP Inhibitor AZD5305, Tremelimumab, 745013-59-6, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer, ticilimumab, Tremelimumab-actl
OHSU Knight Cancer Institute, American Association for Cancer Research, Oregon Health and Science University, Genentech, Inc., Cardiff Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
06/26
02/28
NCT05549661: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Recruiting
1
25
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib, 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myelodysplastic/Myeloproliferative Neoplasm
06/27
12/27
NCT04446793: Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

No Longer Available
N/A
NA
Onvansertib, Bevacizumab, FOLFIRI
Cardiff Oncology
Metastatic Colorectal Cancer, KRAS Gene Mutation
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
onvansertib (PCM-075) / Cardiff Oncology
NCT03414034: Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Checkmark In combination with Zytiga in mCRPC at EMUC 2019
Nov 2019 - Nov 2019: In combination with Zytiga in mCRPC at EMUC 2019
Checkmark In combination with Zytiga in patients with mCRPC
Feb 2019 - Feb 2019: In combination with Zytiga in patients with mCRPC
Completed
2
72
US
Onvansertib, PCM-075, Abiraterone, Prednisone
Cardiff Oncology
Metastatic Castration-Resistant Prostate Cancer
10/23
10/23
NCT04752696: Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma

Completed
2
43
US
Onvansertib, PCM-075, Nanoliposomal irinotecan, Onivyde, Nal-IRI, Leucovorin, Fluorouracil, 5-FU
Cardiff Oncology
Pancreatic Ductal Adenocarcinoma
12/24
12/24
NCT06398587: Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Withdrawn
2
35
US
Onvansertib, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, PLK1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Electrocardiography, ECG, EKG, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Biospecimen Collected, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
OHSU Knight Cancer Institute, Oregon Health and Science University
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
05/26
06/27
ONSEMBLE, NCT05593328: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Completed
2
23
US
Onvansertib, FOLFIRI, Bevacizumab
Cardiff Oncology
Colorectal Cancer, Metastatic Colorectal Cancer
12/24
12/24
CRDF-004, NCT06106308: Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation

Recruiting
2
90
US
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Cardiff Oncology, Pfizer
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
11/26
01/27
NCT05450965: Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Recruiting
2
37
US
Onvansertib
Taofeek Owonikoko, Cardiff Oncology, National Cancer Institute (NCI)
Small-cell Lung Cancer, Small Cell Lung Carcinoma
08/27
11/27
NCT03829410: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Checkmark Data from trial in combination with Folfiri and bevacizumab for metastatic CRC at ESMO 2022
Sep 2022 - Sep 2022: Data from trial in combination with Folfiri and bevacizumab for metastatic CRC at ESMO 2022
Checkmark Data rom trial in combination with Folfiri and bevacizumab for metastatic colorectal cancer
Jan 2022 - Jan 2022: Data rom trial in combination with Folfiri and bevacizumab for metastatic colorectal cancer
Completed
1/2
68
US
Onvansertib, PCM-075, Bevacizumab, Avastin®, FOLFIRI
Cardiff Oncology
Metastatic Colorectal Cancer, KRAS Gene Mutation
01/24
01/24
PANCONVA, NCT06736717: Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Recruiting
1/2
21
US
Onvansertib, PCM-075, NMS-1286937, NALIRIFOX
University of Kansas Medical Center, Cardiff Oncology
Pancreatic Cancer
07/26
01/27
NCT05383196: Onvansertib + Paclitaxel in TNBC

Active, not recruiting
1/2
50
US
Onvansertib, NMS-1286937, Paclitaxel, Paclitaxel Injection
Antonio Giordano, MD, Cardiff Oncology
Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
02/26
02/29
NCT04005690: Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
1
90
US
Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Onvansertib, 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Azenosertib, ZN-c3, KP-2638, C29H34N8O2, Saruparib, AZD5305, 2589531-76-8, AZD 5305, AZD-5305, PARP Inhibitor AZD5305, Tremelimumab, 745013-59-6, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer, ticilimumab, Tremelimumab-actl
OHSU Knight Cancer Institute, American Association for Cancer Research, Oregon Health and Science University, Genentech, Inc., Cardiff Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
06/26
02/28
NCT05549661: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Recruiting
1
25
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib, 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myelodysplastic/Myeloproliferative Neoplasm
06/27
12/27
NCT04446793: Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

No Longer Available
N/A
NA
Onvansertib, Bevacizumab, FOLFIRI
Cardiff Oncology
Metastatic Colorectal Cancer, KRAS Gene Mutation
 
 

Download Options